[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100184682":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":45,"centralContacts":31,"locations":48,"responsibleParty":60,"collaborators":31,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":31,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":31,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":31,"overallStatus":81,"whyStopped":31,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Boehringer Ingelheim","INDUSTRY",[8,14,19,22],{"label":9,"type":10,"description":11,"interventionNames":12},"1 Nintedanib (Reference)","EXPERIMENTAL","single dose, oral with 240 ml water",[13],"Drug: Nintedanib",{"label":15,"type":10,"description":16,"interventionNames":17},"2 Nintedanib + Ketoconazole (Test)","Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water",[18,13],"Drug: Ketoconazole",{"label":20,"type":10,"description":11,"interventionNames":21},"3 Nintedanib (Reference)",[13],{"label":23,"type":10,"description":16,"interventionNames":24},"4 Nintedanib + Ketoconazole (Test)",[13,18],[26,32,35,39,41,43],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Nintedanib","low or medium dose depending on pilot part",[20],null,{"type":27,"name":28,"description":33,"armGroupLabels":34,"otherNames":31},"low dose oral administration",[9],{"type":27,"name":36,"description":37,"armGroupLabels":38,"otherNames":31},"Ketoconazole","oral administration",[15],{"type":27,"name":28,"description":33,"armGroupLabels":40,"otherNames":31},[15],{"type":27,"name":28,"description":29,"armGroupLabels":42,"otherNames":31},[23],{"type":27,"name":36,"description":37,"armGroupLabels":44,"otherNames":31},[23],[46],{"name":5,"affiliation":5,"role":47},"STUDY_CHAIR",[49],{"facility":50,"status":31,"city":51,"state":31,"zip":31,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":31},"1199.161.1 Boehringer Ingelheim Investigational Site","Biberach","Germany","DE",{"type":55,"coordinates":56},"Point",[57,58],8.03333,48.33333,{"lat":58,"lon":57},{"type":61,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100184682","phase-1-investigation-of-drug-drug-interaction-of-nintedanib-and-ketoconazole-in-healthy-male-volunteers-100184682",true,"NCT01679613","Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers","Relative Bioavailability of Nintedanib Given Alone and in Combination With Ketoconazole at Steady State in Healthy Male Volunteers (an Open-label, Randomised, Two-way Cross-over Clinical Phase I Study)","Inclusion criteria:\n\n1\\. healthy male subjects\n\nExclusion criteria:\n\n1\\. Any relevant deviation from healthy conditions","MALE","18 Years","55 Years",{"count":73,"type":74},34,"ACTUAL","INTERVENTIONAL",[77],"PHASE1","The objective of the current study is to investigate the relative bioavailability of a single dose of nintedanib low or high dose with and without coadministration of ketoconazole at steady state",[80],"Healthy","COMPLETED","2014-11-26",{"date":84,"type":85},"2014-11-27","ESTIMATED",{"date":87,"type":31},"2012-09",{"date":89,"type":74},"2012-11",{"name":5,"class":6},1]